Login
$ANNX
$3.61 +$0.04 (1.12%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Douglas Love Also a director
PRESIDENT AND CEO
Title from the Form 4 dated Sep 24, 2026
58 Not stated $3,579,202
Jennifer Lew
Executive Vice President and Chief Financial Officer
Not stated Since 2019
7 years
$1,341,274
Rick Artis
Executive Vice President and Chief Scientific Officer
Not stated Since 2023
3 years
Not reported
Ted Yednock
Chief Innovation Officer
Not stated Since 2021
5 years
$1,379,052
Michael Overdorf
Executive Vice President and Chief Business Officer
Not stated Since 2020
6 years
Not reported
Jamie Dananberg
Executive Vice President and Chief Medical Officer
Not stated Since 2023
3 years
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Aug 10, 2026

Directors
8
serving now
Independent
0 of 1
stated in the proxy; 7 not stated
Average tenure
5.5 years
from year joined
CEO also chairs the board
No
Thomas G. Wiggans
Director Age On board Independent Committees Other public boards 2025 pay Source
Douglas Love
58 2014
12 years
Not independent None stated None stated Paid as CEO
Bettina M. Cockroft
59 2022
4 years
Not stated
Audit Committee
CNS Pharmaceuticals, Inc. $162,215
William H. Carson, M.D.
67 2021
5 years
Not stated None stated None stated $164,215
William (BJ) Jones, Jr.
62 2025
1 year
Not stated None stated Apogee Therapeutics, Inc. $475,989
Jung E. Choi
56 2020
6 years
Not stated None stated None stated $164,215
William D. Waddill
69 2021
5 years
Not stated
Audit Committee · Chair
Arrowhead Pharmaceuticals, Inc. $171,215
Mark S. Blumenkranz, M.D., M.S.S. Joined Aug 10, 2026
- - -
Audit Committee Science and Technology committee
- -
Thomas G. Wiggans Leaving at the meeting
Not stated Not stated Not stated None stated None stated $192,215

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

No related-party transactions disclosed

The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support